₹7.57 Cr Revenue in Q1 FY27, up 166% YoY; Net Profit rises to ₹0.22 Cr
Beryl Drugs reported a significant top-line expansion in Q1 FY27, with total revenue reaching ₹7.57 Cr, a 166% increase from ₹2.84 Cr in Q1 FY26. Net profit surged to ₹22.08 Lakhs compared to just ₹2.11 Lakhs in the same period last year, although it declined sequentially from ₹56.25 Lakhs in Q4 FY26. The sequential profit drop is attributed to a sharp spike in 'Other Expenses,' which rose to ₹1.86 Cr from ₹0.38 Cr in the previous quarter. Despite margin pressure, the company remains profitable with an EPS of ₹0.47 for the quarter.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has achieved a significant scale-up in quarterly revenue, moving from a quarterly average of ~₹4.8 Cr in FY26 to over ₹7.5 Cr in Q1 FY27.
ஏன் இது முக்கியம்For a micro-cap company with a ₹12 Cr market capitalization, this level of revenue growth suggests a potential structural shift in business volume or the execution of a large new contract.
Revenue (Q1 FY27): ₹7.57 கோடிYoY Revenue Growth: 166%Q1 வருவாய் vs TTM வருவாய்: ~39.8%Net Profit (Q1 FY27): ₹0.22 கோடிOther Expenses: ₹1.86 கோடி
📅 குறுகிய காலம்The strong YoY growth is likely to be viewed positively by the market, though the sequential decline in PAT due to higher expenses may lead to some volatility.
📈 நீண்ட காலம்If the company can maintain this higher revenue base while optimizing operating costs, it could lead to a significant re-rating of the stock given its small base.
⚠ அபாய எச்சரிக்கைகள்
🔬 ஆழமான மல்டிபேக்கர் பகுப்பாய்வுக்காகக் குறிக்கப்பட்டவை — சுருக்கங்களைப் பார்க்க →
- Significant volatility in 'Other Expenses'
- Low promoter holding at 27.8%
- Micro-cap liquidity risk
👀 கவனிக்க வேண்டியவை
Investors should monitor if this elevated revenue run-rate is sustainable over the coming quarters and watch for any management commentary regarding the spike in 'Other Expenses' which impacted sequential margins.
